

Press Release

Abliva AB (publ), 556595-6538
01 June 2020 08:30:00 CEST - Lund,
Sweden



Abliva arranges virtual Capital Markets Day on 23 June

Abliva AB (Nasdaq Stockholm: ABLI), invites to a virtual capital markets day on 23 June at 3.00 - 4.30 p.m. CEST. The theme of the day will be the company's new strategic focus on primary mitochondrial disease, the most important pharmaceutical projects and the market potential.

The basis for the company's strategic direction will be highlighted. Furthermore, the major medical needs in primary mitochondrial disease, the competitive situation and the market. The opportunities in the field of orphan drugs will be addressed.

The plans and clinical developments for the key projects KL1333 and NV354 will also be described.

External as well as internal participators will provide a clinical perspective and an investor perspective on Abliva's operations. It will also be possible to ask questions to the company. The meeting will mostly be held in Swedish.

Abliva AB is the new name that replaces the former NeuroVive Pharmaceutical AB. The name change is in line with the company's strengthened focus on mitochondrial disease. Abliva's main projects, KL1333 and NV354, are both focused on primary mitochondrial diseases. The company's drug candidate, NeuroSTAT, is planned after non-dilutive financing to be transferred into a separate company to give the project the best opportunities for resource allocation and further development to the market.

Further information on programs and participators will be published shortly. In the meantime, please book the afternoon in your calendars.

A link to the Capital Markets Day will be available on Abliva's website: www.abliva.com.
Questions can be sent to: ir@abliva.com.

Welcome on 23 June!

Press Release

Abliva AB (publ), 556595-6538
01 June 2020 08:30:00 CEST - Lund,
Sweden



For more information, please contact:

Catharina Johansson, CFO, IR & Communications
+46 (0)46-275 62 21, ir@abliva.com

Abliva AB (publ)

Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard)
info@abliva.com, www.abliva.com

For news subscription, please visit: <http://abliva.com/press-releases/subscription-page/>

Follow us on LinkedIn: <https://www.linkedin.com/company/abliva>

Subscribe to our YouTube channel: <https://www.youtube.com/channel/UCChqP7Ky5caXtp72CELhD6Mg>

About Us

Abliva AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects. Abliva's ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under the NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). Abliva is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).

Attachments

[Abliva arranges virtual Capital Markets Day on 23 June](#)